Novartis
Novartis says it did not send substances for chemical weapons to Syria
July 1, 2019Sales and Marketing Brenntag, Novartis, Syria, chemical weapons, pharma, war
Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to …
Top Ten most popular articles on Pharmafile.com this week
June 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Allergan, Bristol-Myers Squibb, China, GSK, Novartis, Takeda, brexit
This week was diverse as always in terms of news coming out of the pharma industry, but the biggest news …
Novartis provides promising update on Cosentyx in plaque psoriasis
June 26, 2019Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that …
Glenmark signs deal with Novartis over distribution in Brazil
June 24, 2019Sales and Marketing Brazil, Glenmark, Latin America, Novartis, distribution, pharma
Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil. …
Novartis Pharma head to become new Sanofi CEO
June 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Paul Hudson, appointment, olivier brandicourt
French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with …
Novartis Pharma head to become new Sanofi CEO
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Paul Hudson, Sanofi, appointment, olivier brandicourt, pharma
French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with …
First-of-its-kind data shows Novartis’ iscalimab extends survival of transplanted kidneys
June 6, 2019Research and Development Novartis, iscalimab, kidney transplant, pharma, transplant
In a first-of-its-kind reveal, Novartis has presented histology data for iscalimab (CFZ533) at the American Transplant Congress (ATC) which indicates …
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
Top Ten most popular articles on Pharmafile.com this week!
May 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA, GSK, Novartis, Pfizer, environment, opioids, pharma, pricing
The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …
Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma
May 30, 2019Research and Development Novartis, QVM149, asthma, pharma
Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Sandoz is first multinational to secure generic approval under new Chinese guidelines
May 20, 2019Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Novartis’ Kymriah to be covered by Japan’s national insurance system
May 16, 2019Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …
Top Ten most popular articles on Pharmafile.com this week!
May 10, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma
This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …
Latest content
FibroFind appoints Lee Borthwick as CEO
